AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05081401 — intervention group
Intervention type: OTHER
Intervention: This is a non-intervention observational study.
Description: No applicable intervention. This is a secondary data analysis observational study.
Study NCT04893915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: -Lymphodepleting regimen
Study NCT04893915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Lymphodepleting regimen
Study NCT04523857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study NCT04523857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study NCT04893915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Leukapheresis
Description: -Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
Study NCT04893915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: -IL-2 will start approximately 2-4 hours after the NK cell infusions.
Study NCT06495021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Pump Osteopathic Manipulative Therapy
Description: OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
Study NCT06540963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tablet
Study NCT06540963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: IV
Study NCT06421584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical telementoring
Description: The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
Study NCT05184582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
Study NCT05974930 — intervention group
Intervention type: DEVICE
Intervention: IVUS imaging for primary PCI guidance
Description: Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
Study NCT05188664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
Study NCT05188664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
Study NCT05236608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered together with ADG106 via intravenous infusion.
Study NCT05236608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: Administered as an intravenous infusion over 90 minutes.
Study NCT05358275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: ordinary cyst enucleation
Study NCT05859529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JS002
Description: The drug was administered by a single subcutaneous injection
Study NCT06648707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dual-task training
Description: Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.
Study NCT06190392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODS Modified simplified diagnostic strategy
Description: The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied.
Study NCT05586555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pupillometry (Eve-tracking measurements)
Description: Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
Study NCT05586555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pupillometry (Eve-tracking measurements)
Description: Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
Study NCT06467903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .
Description: second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
Study NCT06091735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSS
Description: experimental
Study NCT06091735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSS+Linzess
Description: experimental
Study NCT06091735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG-Interferon Alfa
Description: Placebo Comparator
Study NCT06178107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LP-LDL Probiotic
Description: LP-LDL a dietary food supplement probiotic
Study NCT06178107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo comparator Maltodextrin
Study NCT05350163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
Study NCT04276233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
Study NCT04276233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
Study NCT04733053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Description: The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight.
Study NCT04733053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
Study NCT04733053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
Study NCT05268510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
Study NCT05268510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
Study NCT05268510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
Study NCT05268510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapOX
Description: Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
Study NCT06577987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CID-078 Monotherapy
Description: Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
Study NCT05152108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI feasibility test
Description: Testing the feasibility of BCI device by determining the accuracy of BCI control
Study NCT05947864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological samples (blood and oral fluid)
Description: For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)
Study NCT05947864 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological samples (blood and oral fluid)
Description: For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)
Study NCT06090565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Two 400 mg tablets will be administered orally to equal a 800 mg dose.
Study NCT06090565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: One 100 mg tablet will be administered orally twice a day for 7 days
Study NCT06090565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxon
Description: Dose of 1 g intramuscular one time
Study NCT06090565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Four 500 mg tablets will be administered orally to equal a 2 g dose.
Study NCT05702138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
Study NCT05702138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
Study NCT05505344 — intervention group
Intervention type: DEVICE
Intervention: VentriJect Seismofit validation
Description: All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
Study NCT06227897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib 110 mg per day orally for 3 years.
Study NCT04787107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Chair Massage
Description: Healthcare staff will be placed into either massage or break intervention
Study NCT06322888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Program
Description: A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
Study NCT05567250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Telephone-based ACEs care coordination
Description: The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
Study NCT06312202 — intervention group
Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
Study NCT06415461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PremierMaxCB®-Platinum (CFL001);
Description: Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
Study NCT05210491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of eyelid positioning in increasing brightness levels
Description: Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
Study NCT06038669 — intervention group
Intervention type: DEVICE
Intervention: Dried blood spot device
Description: Patients will be asked to provide a dried blood spot sample
Study NCT06038669 — intervention group
Intervention type: OTHER
Intervention: Healthcare professional interviews
Description: Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
Study NCT04448977 — intervention group
Intervention type: DRUG
Intervention: Ocrevus
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education.
Study NCT05287646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Suspension First
Description: Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
Study NCT05287646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevated Vacuum Suspension First
Description: Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
Study NCT06121271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 DOTATATE (Lutathera®)
Description: Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
Study NCT06538870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of dental implants
Description: Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.
Study NCT05977699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol aqueous solution
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
Study NCT05977699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol pressurized metered dose inhaler
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
Study NCT05977699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
Study NCT04276142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ceprica (additional to treatment as usual)
Description: ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
Study NCT04276142 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: active control intervention (additional to treatment as usual)
Description: the active control intervention contains psychoeducational content regarding migraine
Study NCT06565416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategies
Description: Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
Study NCT05620082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard liquid-based oral nutritional supplement
Description: An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
Study NCT05620082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified porridge
Description: Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
Study NCT04347304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate (20 grams) per day providing 508 mg of polyphenols
Description: subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
Study NCT05408156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insoles
Description: semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)